Numerous studies have confirmed that DCs are crucial for tumor immunity in gastric carcinoma.3 Many clinical trials have tested DC‐based gastric cancer treatment regimens.4 Some DC‐associated inflammatory factors are predictive of gastric carcinoma prognosis.5, 6 CD83 + DC cells in primary gastric tumors and regional lymph nodes, as well as human lymphocyte antigen (HLA)‐G‐expressing DCs in peripheral blood, are associated with a poor gastric carcinoma prognosis.7 Two subtypes of circulating DC precursor populations, DC1 and DC2, have been clearly identified to date. The gene discussed is ZDHHC4; the disease is gastric cancer.